CELL DEATH DIS 润色咨询

Cell Death & Disease

出版年份:2010 年文章数:6499 投稿命中率: 开通期刊会员,数据随心看

出版周期:Monthly 自引率:2.8% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2024-02-06 ms3000001660419742 来自台湾省

    偏重的研究方向:幹細胞
    经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ

    5

    展开5条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2023-07-01 Shawnwang 来自广东省

    偏重的研究方向:细胞死亡
    经验分享:刚刚submit,上帝保佑,沾沾大家的喜气

    10

    展开10条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2024-03-14 tou16689595638 来自广西

    投了一篇都很顺利,不错,可以聊聊

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2024-01-16 ms4000000731438466 来自天津

    偏重的研究方向:肿瘤
    经验分享:提交10天,显示状态为Decision made什么情况?

    6

    展开6条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2023-07-13 ms7000000921712169 来自广东省

    审稿速度:3.0 | 投稿命中率:25.0
    偏重的研究方向:呼吸疾病
    经验分享:刚刚中了一篇,比较顺利

    4

    展开4条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2023-07-07 36192448 来自湖南省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:干细胞;细胞死亡
    经验分享:一审84天,二审7天,目前decision made 7天还没消息

    7

    展开7条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2024-03-05 超超不吵吵 来自湖南省

    投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2022-10-02 ms4000000661887175

    请问有投综述的吗?从提交文章到有结果大概是什么流程?

    3

    展开3条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2024-03-04 维新Tuo1887878 来自广西

    qudao tougao15994441457

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=2186209, encodeId=09e8218620984, content=偏重的研究方向:幹細胞<br>经验分享:1/11 投稿 還沒有editor assigned,祝大家投稿順利 來沾沾大家的喜氣QQ, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=17, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=17858640518, createdName=ms3000001660419742, createdTime=Tue Feb 06 14:04:30 CST 2024, time=2024-02-06, status=1, ipAttribution=台湾省), GetPortalCommentsPageByObjectIdResponse(id=2145879, encodeId=116a21458e967, content=偏重的研究方向:细胞死亡<br>经验分享:刚刚submit,上帝保佑,沾沾大家的喜气, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=126, replyNumber=10, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=29a11951706, createdName=Shawnwang, createdTime=Sat Jul 01 23:23:58 CST 2023, time=2023-07-01, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2193202, encodeId=1ebf2193202dd, content=投了一篇都很顺利,不错,可以聊聊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/202403/4c373b436e9b457fbdd952337fdd05c5-8sZ2pBl1gPrG.jpg, createdBy=e7e09211753, createdName=tou16689595638, createdTime=Thu Mar 14 16:03:05 CST 2024, time=2024-03-14, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=2181970, encodeId=170c21819e01b, content=偏重的研究方向:肿瘤<br>经验分享:提交10天,显示状态为Decision made什么情况?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=26, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e909137780, createdName=ms4000000731438466, createdTime=Tue Jan 16 13:11:31 CST 2024, time=2024-01-16, status=1, ipAttribution=天津), GetPortalCommentsPageByObjectIdResponse(id=2147888, encodeId=f2bd214e88842, content=审稿速度:3.0 | 投稿命中率:25.0<br>偏重的研究方向:呼吸疾病<br>经验分享:刚刚中了一篇,比较顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=55, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c0578477592, createdName=ms7000000921712169, createdTime=Thu Jul 13 19:57:12 CST 2023, time=2023-07-13, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2146801, encodeId=f60321468017c, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:干细胞;细胞死亡<br>经验分享:一审84天,二审7天,目前decision made 7天还没消息, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=73, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe2b2627122, createdName=36192448, createdTime=Fri Jul 07 12:30:24 CST 2023, time=2023-07-07, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2191210, encodeId=b2c02191210ea, content=投了一篇综述,一直是Under Consideration,在第22天左右分配了编辑,然后第5天出现了Reviewer Zip File "Zip of files for Reviewer" ,等待中。<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=6, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Tue Mar 05 19:36:34 CST 2024, time=2024-03-05, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2091499, encodeId=f7a4209149988, content=请问有投综述的吗?从提交文章到有结果大概是什么流程?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=36, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=45516427528, createdName=ms4000000661887175, createdTime=Sun Oct 02 18:07:57 CST 2022, time=2022-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2190984, encodeId=540421909849d, content=qudao tougao15994441457, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=856d9197785, createdName=维新Tuo1887878, createdTime=Mon Mar 04 16:48:41 CST 2024, time=2024-03-04, status=1, ipAttribution=广西), GetPortalCommentsPageByObjectIdResponse(id=892414, encodeId=dbfd89241445, content=审稿速度:2.0 | 版面费用:3990.0<br>偏重的研究方向:肿瘤;代谢<br>经验分享:这里我将自己的投稿过程详细的分享给大家:<br>2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;<br>2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;<br>2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;<br>2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。<br>整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=253, replyNumber=30, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201203/92f08f156b054c6b86f0325ca8b1fdf9/8d711cf9a8f746219a67fdfeece251c2.jpg, createdBy=62ca5338422, createdName=ms7000000270052196, createdTime=Fri Oct 16 10:25:42 CST 2020, time=2020-10-16, status=1, ipAttribution=)]
    2020-10-16 ms7000000270052196

    审稿速度:2.0 | 版面费用:3990.0
    偏重的研究方向:肿瘤;代谢
    经验分享:这里我将自己的投稿过程详细的分享给大家:
    2020.05.29 第一次提交投稿,7~10天左右分配编辑发邮件提示收到邮件;
    2020.06.29 收到两位审稿专家的意见为大修,编辑给了两个月时间;
    2020.08.24 二次提交修回稿件,由于缺少文件被退回,两天后重新提交;
    2020.09.22 收到邮件通知官方接收,来来回回修改几次格式以后收取版面费校样,半个月左右online。
    整个投稿过程比较顺利,审稿人提的意见比较中肯,看的也很仔细,大到文章的整体结构与思路,小到一个标点符号,所以我整整补了两个月的实验并且回复信写了将近20多页PDF,最终得到了审稿人的认可与鼓励。个人认为该杂志对文章创新性要求并不十分高,但是对数据量要求较高,另外版面费比较贵。所以数据多不差钱的小伙伴值得一试。希望可以给迷惘投稿的同行们带来一点讯息,以上仅为个人意见,请结合自身情况酌情参考。谢谢大家。

    30

    展开30条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分